Drug Profile
Belapectin - Galectin Therapeutics
Alternative Names: Galactoarabino-rhamnogalaturonate; GR MD 02Latest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator Galectin Therapeutics
- Developer Galectin Therapeutics; Providence Cancer Center; Providence Health & Services
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Antipsoriatics; Carbohydrates; Hepatoprotectants; Polysaccharides; Skin disorder therapies; Small molecules
- Mechanism of Action Galectin 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Head and neck cancer; Lung cancer; Malignant melanoma; Orofacial cancer
Highest Development Phases
- Phase II/III Liver cirrhosis
- Phase II Atopic dermatitis; Hepatic fibrosis; Plaque psoriasis
- Phase I Head and neck cancer; Lung cancer; Malignant melanoma
- Preclinical Arrhythmias; Pulmonary arterial hypertension; Pulmonary fibrosis
- No development reported Breast cancer; Diabetic nephropathies; Fibrosis; Orofacial cancer; Prostate cancer; Renal fibrosis
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 11 Oct 2023 Adverse events and pharmacokinetics data from a phase IIb/III trial in Liver cirrhosis presented at the The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases Session (AASLD-2023)
- 11 Oct 2023 Adverse events data from a phase I trial in Hepatic impairment presented at the The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases Session (AASLD-2023)
- 11 Oct 2023 Efficacy data from a phase II trial in Hepatic fibrosis and Liver cirrhosis presented at the The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases Session (AASLD-2023)